Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.
HealthDay News — Two doses of the recombinant zoster vaccine (RZV) are effective in older adults, including immunocompromised adults, according to a study published online October 13 in the Annals of ...
Patients prescribed SGLT2 inhibitors less likely to exhibit nodule growth and to undergo a surgical intervention.
HealthDay News — Low-dose ketamine for chronic refractory pain shows therapeutic benefit and high tolerability, according to a study published online October 5 in Regional Anesthesia & Pain Medicine.
The new CalRx insulin will work as a generic version of glargine and could save patients $2000 to $4000 per year.
HealthDay News — For patients with focal treatment-resistant epilepsy (FTRE), seizure frequency improves over time, according to a study published online October 20 in JAMA Neurology.
California officials said the new Clade 1 cases were found in one person in Long Beach and two in Los Angeles. All three were hospitalized and have since been discharged to recover at home in ...
The approval was based on the SOUL trial, which evaluated oral semaglutide in adults 50 years and older with T2DM and established CV disease and/or chronic kidney disease.
Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.
The Food and Drug Administration (FDA) has approved Gazyva ® (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
Both low and high increases in use were negatively but weakly associated with adolescent cognitive performance 2 years later.
Association between continued smoking and all-cause mortality also seen in patients with advanced-stage cancer.